Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 25, 2014, 127 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $158.00 to $38,255,692.50.

Highlighted Stocks Traded by Insiders:

Eplus (PLUS) - FREE Research Report

Marron Mark P, who is Chief Operating Officer at Eplus, sold 7,500 shares at $69.43 on Nov. 25, 2014. Following this transaction, the Chief Operating Officer owned 35,929 shares meaning that the stake was reduced by 17.27% with the 7,500-share transaction.

The shares most recently traded at $69.75, up $0.32, or 0.46% since the insider transaction. Historical insider transactions for Eplus go as follows:

  • 4-Week # shares sold: 12,635
  • 12-Week # shares sold: 22,635
  • 24-Week # shares sold: 25,433

The average volume for Eplus has been 32,800 shares per day over the past 30 days. Eplus has a market cap of $512.6 million and is part of the technology sector and computer software & services industry. Shares are up 22.1% year-to-date as of the close of trading on Tuesday.

ePlus inc., through its subsidiaries, provides information technology (IT) products and services, flexible leasing and financing solutions, and enterprise supply management in the United States. It operates through two segments: Technology and Financing. The company has a P/E ratio of 13.3. Currently, there are 3 analysts who rate Eplus a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PLUS - FREE

TheStreet Quant Ratings

rates Eplus as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Eplus Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

LyondellBasell Industries (LYB) - FREE Research Report

Carroll Milton, who is Director at LyondellBasell Industries, sold 2,720 shares at $90.76 on Nov. 25, 2014. Following this transaction, the Director owned 4,899 shares meaning that the stake was reduced by 35.7% with the 2,720-share transaction.

The shares most recently traded at $88.95, down $1.81, or 2.03% since the insider transaction. Historical insider transactions for LyondellBasell Industries go as follows:

  • 4-Week # shares sold: 34,977
  • 12-Week # shares sold: 34,977
  • 24-Week # shares bought: 8.4 million
  • 24-Week # shares sold: 39,118

The average volume for LyondellBasell Industries has been 5.1 million shares per day over the past 30 days. LyondellBasell Industries has a market cap of $45.3 billion and is part of the basic materials sector and chemicals industry. Shares are up 12.92% year-to-date as of the close of trading on Tuesday.

LyondellBasell Industries N.V., together with its subsidiaries, manufactures chemicals and polymers; refines crude oil; produces gasoline blending components; and develops and licenses technologies for production of polymers. The stock currently has a dividend yield of 3.09%. The company has a P/E ratio of 10.7. Currently, there are 11 analysts who rate LyondellBasell Industries a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LYB - FREE

TheStreet Quant Ratings

rates LyondellBasell Industries as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full

LyondellBasell Industries Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cardica (CRDC) - FREE Research Report

Petersmeyer Gary S, who is Director at Cardica, bought 25,000 shares at $0.60 on Nov. 25, 2014. Following this transaction, the Director owned 25,000 shares meaning that the stake was boosted by 100% with the 25,000-share transaction.

Historical insider transactions for Cardica go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 5,000
  • 24-Week # shares bought: 5,000

The average volume for Cardica has been 318,100 shares per day over the past 30 days. Cardica has a market cap of $54.3 million and is part of the health care sector and health services industry. Shares are down 36.41% year-to-date as of the close of trading on Tuesday.

Cardica, Inc. designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery in the United States and internationally. Currently, there is 1 analyst who rates Cardica a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRDC - FREE

TheStreet Quant Ratings

rates Cardica as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally disappointing historical performance in the stock itself. Get the full

Cardica Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null